Loading...
XSHG
603222
Market cap783mUSD
Jul 09, Last price  
10.12CNY
1D
10.00%
1Q
-0.88%
Jan 2017
-23.91%
IPO
143.02%
Name

Chimin Health Management Co Ltd

Chart & Performance

D1W1MN
XSHG:603222 chart
P/E
P/S
7.77
EPS
Div Yield, %
Shrs. gr., 5y
3.15%
Rev. gr., 5y
-4.87%
Revenues
684m
-11.88%
548,363,132582,752,013559,420,132488,305,659448,595,640450,378,618602,898,707697,831,630771,279,230877,640,0181,098,469,878837,236,200894,508,694775,728,782683,603,421
Net income
-246m
L+311.28%
67,775,03474,560,10781,247,76057,583,49451,747,10740,893,90852,884,36232,062,82369,198,6946,397,228147,521,34734,455,153-65,480,413-59,711,714-245,582,547
CFO
-10m
L
32,898,924169,879,357108,185,75677,356,24887,463,44672,115,82466,493,811123,987,469152,773,604166,292,926289,491,045204,653,775140,201,97572,985,921-10,351,563
Dividend
Jun 07, 20230.02 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chimin Health Management Co., Ltd., formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd., is a Chinese enterprise specializing in the research, production, and distribution of pharmaceuticals for human use and medical apparatus. Its product offerings include diverse medical packaging options, such as non-PVC soft bags with various valve configurations (e.g., double-tube double valves, single valves, single-tube double valves), plastic bottles, and other specialized containers. The company also supplies an extensive array of injection and infusion devices, encompassing safety syringes, safety injection needles, sterile syringes, irrigators, dispensers, insulin syringes, as well as standard and precision filter infusion sets. Beyond these, Chimin Health Management provides in-vitro diagnostic products, hemodialysis supplies, and delivers medical services. The firm was established in 1996 and maintains its principal operations in Huangyan, China.
IPO date
Feb 17, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT